Brain 17 Vienna

Bevacizumab

• Only low risk for CNS hemorrhage in patients with NSCLC and brain mets who are treated with bevacizumab

• Potentially strong anti-edema activity

• Bevacizumab alone or in combination with chemotherapy in patients with brain mets from NSCLC:

• Median PFS: 7.8 months • Median OS: 14.1 months

• WBRT + bevacizumab in patients with brain mets (REBECA): • Safe, but clinical benefit remains unclear

Socinski et al. J Clin Oncol 2009 De Braganca et al. J Neurooncol 2010 Lévy et al. Ann Oncol 2014